Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy

European Journal of Cancer Part A

Volumn 32, Issue 9, 1996, Pages 1523-1529

  Fauser, A A ^a   Duclos, B ^b   Chemaissani, A ^c   Del Favero, A ^d   Cognetti, F ^e   Diaz Rubio, E ^f   Cortes Funes, H ^g   Conte, P F ^h   Dressler, H ⁱ  

^a Klin fur KMT/Hamatologie/Onkologie   (Germany)

^b HÔPITAL CIVIL   (France)

^c KRANKENHAUS MERHEIM   (Germany)

^d UNIVERSITY OF PERUGIA   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h SANTA CHIARA HOSPITAL   (Italy)

ⁱ Praktischer Arzt   (Germany)

Author keywords

5 HT3 receptor antagonist; Anti emetic; Carboplatin; Clinical trial; Cyclophosphamide; Dolasetron; Doxorubicin; Emesis; Nausea; Ondansetron

Indexed keywords

CARBOPLATIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOLASETRON MESILATE; DOXORUBICIN; EPIRUBICIN; IFOSFAMIDE; ONDANSETRON;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 0030218865     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00132-3     Document Type: Article

References (35)

1. 1. Coates A, Abraham S, Kaye SB, et al. On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983, 19, 203-208.
2. 2. Cooke CE, Mehra IV. Oral ondansetron for preventing nausea and vomiting. Am J Hosp Pharm 1994, 51, 762-771.
3. 3. Cooper S, Georgiou V. The impact of cytotoxic chemotherapy - perspectives from patients, specialists and nurses. Eur J Cancer 1992, 28A (Suppl. 1), S36-S38.
4. 4. Gralla RJ. Current issues in the management of nausea and vomiting. Ann Oncol 1993, 4 (Suppl. 3), S3-S7.
5. 5. Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med 1993, 329, 1790-1796.
6. 3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs 1991, 42, 551-568.
7. 3 antagonists MDL 73147EF (dolasetron mesylate) and MDL 74156 in NG108-15 neuroblastoma × glioma cells. Eur J Pharmacol 1992, 219, 9-13.
8. 8. Galvan M, Gittos MW, Fatmi M. Dolasetron mesylate. Drugs Future 1993, 18, 506-509.
9. 3 receptors. Drug Devel Res 1993, 28, 87-93.
10. 3 receptor antagonist. Drug Dev Res 1995, 34, 289-296.
11. 11. Boxenbaum H, Gillespie T, Heck K, Hahne W. Human dolasetron pharmacokinetics: I. Disposition following single-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 1992, 13, 693-701.
12. 12. Dixon RM, Cramer M, Conway DW, et al. Single-dose, placebo-controlled phase I study of oral dolasetron. Pharmacotherapy 1996, 16, 245-252.
13. 13. Hunt TL, Cramer M, Christy-Billet J, et al. Multiple-dose, placebo-controlled phase I study of oral dolasetron. Pharmacotherapy 1996, 16, 253-260.
14. 3 antagonist, in cancer patients treated with cisplatin. Am J Clin Oncol 1994, 17, 97-102.
15. 15. Hesketh PJ, Gandara DR, Hesketh AM, et al. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Support Care Cancer 1996, 4, 141-146.
16. 3 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann Oncol 1993, 4, 481-484.
17. 17. Kris MG, Grunberg SM, Gralla RH, et al. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 1994, 12, 1045-1049.
18. 18. Merrouche Y, Catimel G, Rebattu P, et al. A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy. Ann Oncol 1994, 5, 549-551.
19. 19. Harman GS, Omura GA, Ryan K, et al. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis. Cancer Chemother Pharmacol, in press.
20. 20. Kasimis B, Tapazoglou E, Schulman P, et al. A double-blind, randomized study of two different dose regimens of intravenous (IV) dolasetron (DOL) in patients (PTS) receiving high-dose cisplatin (CDDP) chemotherapy (abstract). Proc Am Soc Clin Oncol 1994, 13, 446.
21. 21. Yeilding A, Bertoli L, Eisenberg P, et al. Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy. Am J Clin Oncol, in press.
22. 22. Rubenstein E, Kalman L, Hainsworth J, et al. Dose-response trial across 4 oral doses of dolasetron (D) for emesis prevention after moderately emetogenic chemotherapy (CT) (abstract). Proc Am Soc Clin Oncol 1995, 14, 527.
23. 23. Beck TM, Ciociola AA, Jones SE, et al. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 1993, 118, 407-413.
24. 24. Buser KS, Joss RA, Piquet D, et al. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study. Ann Oncol 1993, 4, 475-479.
25. 25. Fraschini G, Ciociola A, Esparza L, et al. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. J Clin Oncol 1991, 9, 1268-1274.
26. 26. Markham A, Sorkin EM. Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs 1993, 45, 931-952.
27. 27. Roila F, Tonato M, Basurto C, et al. Ondansetron. Eur J Cancer 1993, 29A (Suppl. 1), S16-S21.
28. 28. Morrow GR. Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. J Clin Oncol 1984, 2, 1170-1176.
29. 29. Pollera CF, Giannarelli D. Prognostic factors influencing cisplatin-induced emesis. Cancer 1989, 64, 1117-1122.
30. 30. Beck TM. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials. Semin Oncol 1992, 19 (Suppl. 15), 20-25.
31. 31. Bryson JC. Clinical safety of ondansetron. Semin Oncol 1992, 19 (Suppl. 15), 26-32.
32. 32. Milne RJ, Heel RC. Ondansetron. Therapeutic use as an antiemetic. Drugs 1991, 41, 574-595.
33. 33. Becker MH, Maiman LA. Strategies for enhancing patient compliance. J Comm Health 1980, 6, 113-135.
34. 34. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989, 261, 3273-3277.
35. 35. Gatley MS. To be taken as directed. J R Coll Gen Pract 1968, 16, 39-44.